Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi

S. Sacchi, Raffaella Marcheselli, A. Bari, G. Buda, A.L. Molinari, L. Baldini, D. Vallisa, M. Cesaretti, P. Musto, S. Ronconi, G. Specchia, Franco Silvestris, L. Guardigni, A. Ferrari, Annalisa Chiapella, A.M. Carella, A. Santoro, F. Di Raimondo, Luigi Marcheselli, Samantha Pozzi

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)e196-e199
JournalHaematologica
Volume101
Issue number5
DOIs
Publication statusPublished - 2016

Keywords

  • Efficacy
  • Indolent
  • Lenalidomide
  • Non-follicular lymphoma
  • Recurrent
  • Rituximab
  • Safety

Cite this